Chloride content of solutions used for regional citrate anticoagulation might be responsible for blunting correction of metabolic acidosis during continuous veno-venous hemofiltration

BMC Nephrol. 2016 Aug 26;17(1):119. doi: 10.1186/s12882-016-0334-3.

Abstract

Background: Citrate, the currently preferred anticoagulant for continuous veno-venous hemofiltration (CVVH), may influence acid-base equilibrium.

Methods: The effect of 2 different citrate solutions on acid-base status was assessed according to the Stewart-Figge approach in two consecutive cohorts of critically ill adult patients. The first group received Prismocitrate 10/2 (PC10/2; 10 mmol citrate/L). The next group was treated with Prismocitrate 18/0 (PC18; 18 mmol citrate/L). Both groups received bicarbonate-buffered fluids in post-dilution.

Results: At similar citrate flow, the metabolic acidosis present at baseline in both groups was significantly attenuated in PC18 patients but persisted in PC10/2 patients after 24 h of treatment (median pH 7,42 vs 7,28; p = 0.0001). Acidosis in the PC10/2 group was associated with a decreased strong ion difference and an increased strong ion gap (respectively 43 vs. 51 mmol/L and 17 vs. 12 mmol/L, PC10/2 vs. PC18; both p = 0.001). Chloride flow was higher in PC10/2 than in PC18 subjects (25.9 vs 14.3 mmol/L blood; p < 0.05).

Conclusion: Correction of acidosis was blunted in patients who received 10 mmol citrate/L as regional anticoagulation during CVVH. This could be explained by differences in chloride flow between the applied citrate solutions inducing hyperchloremic acidosis.

Keywords: Acid-base balance; Acidosis; Alkalosis; Anticoagulation; Chloride; Citrate; Continuous veno-venous hemofiltration; Hyperchloremic acidosis; Stewart-Figge approach; Strong ion gap.

Publication types

  • Observational Study

MeSH terms

  • Acid-Base Equilibrium / drug effects
  • Acidosis / blood
  • Acidosis / drug therapy*
  • Acidosis / etiology
  • Acute Kidney Injury / therapy
  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects*
  • Anticoagulants / chemistry*
  • Bicarbonates / therapeutic use
  • Buffers
  • Chlorides / analysis*
  • Citric Acid / adverse effects*
  • Female
  • Hemofiltration / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies

Substances

  • Anticoagulants
  • Bicarbonates
  • Buffers
  • Chlorides
  • Citric Acid